Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease by Johnson, David K. et al.
ORIGINAL CONTRIBUTION
Longitudinal Study of the Transition
From Healthy Aging to Alzheimer Disease
David K. Johnson, PhD; Martha Storandt, PhD; John C. Morris, MD; James E. Galvin, MD, MPH
Background: Detection of the earliest cognitive changes
signifying Alzheimer disease is difficult.
Objective: To model the cognitive decline in preclini-
cal Alzheimer disease.
Design: Longitudinal archival study comparing indi-
viduals who became demented during follow-up and
people who remained nondemented on each of 4 cogni-
tive factors: global, verbal memory, visuospatial, and work-
ing memory.
Setting: Alzheimer Disease Research Center, Washing-
ton University School of Medicine, St Louis, Missouri.
Participants: One hundred thirty-four individuals who
became demented during follow-up and 310 who re-
mained nondemented.
Main Outcome Measures: Inflection point in longi-
tudinal cognitive performance.
Results: The best-fitting model for each of the 4 factors
in the stable group was linear, with a very slight down-
ward trend on all but the Visuospatial factor. In con-
trast, a piecewise model with accelerated slope after a sharp
inflection point provided the best fit for the group that
progressed. The optimal inflection point for all 4 factors
was prior to diagnosis of dementia: Global, 2 years; Ver-
bal and Working Memory, 1 year; and Visuospatial, 3
years. These results were also obtained when data were
limited to the subset (n=44) with autopsy-confirmed Alz-
heimer disease.
Conclusions: There is a sharp inflection point fol-
lowed by accelerating decline in multiple domains of cog-
nition, not just memory, in the preclinical period in Alz-
heimer disease when there is insufficient cognitive decline
to warrant clinical diagnosis using conventional crite-
ria. Early change was seen in tests of visuospatial abil-
ity, most of which were speeded. Research into early de-
tection of cognitive disorders using only episodic memory
tasks may not be sensitive to all of the early manifesta-
tions of disease.
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R ECENT STUDIES HAVE FO-cused on identifying the be-ginning of the transitionfrom healthy aging to de-mentia. As new interven-
tions become available, it will become im-
portant to identify the disease as early as
possible. A piecewise regression analysis
of a measure of episodic memory identi-
fied an inflection point 5 years before di-
agnosis in the Bronx Aging Study.1 A flat
trajectory followed by decline beginning
7 years before diagnosis of dementia was
reported for the same measure in the Bal-
timore Longitudinal Study of Aging,2
which also found decline in executive
function that increased in rate 2 to 3 years
before diagnosis. Episodic memory is not
the only aspect of cognition that can be af-
fected in preclinical Alzheimer disease
(AD).3 Indeed, mild cognitive impair-
ment, often thought to represent a tran-
sitional state between healthy cognitive ag-
ing and AD, is defined on the basis of
deficits in cognitive domains in addition
to memory.4
In this article we examine cognitive do-
mains beyond episodic memory and ex-
ecutive function to test hypotheses about
the existence of inflection points before
clinical diagnosis of dementia. Based on
the identification of common factor struc-
tures in cognitively healthy individuals and
those with AD,5 we examined global men-
tal ability and 3 specific cognitive do-
mains (verbal memory, working memory,
and visuospatial ability) through a long
preclinical period as people developed de-
mentia and compared them with those
who remained cognitively healthy. Re-
sults from longitudinal studies6-9 support
an early observation10 that the overall
course of healthy aging is relatively stable
compared with the cognitive decline, of-
ten precipitous, experienced by those who
develop dementia. We sought to model
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that change to determine when the inflection occurs be-
fore dementia detection and the rate of change after-
ward for different cognitive domains and to validate




Longitudinal archival data were examined from 444 volun-
teers initially aged 60 to 101 years enrolled in the Alzheimer
Disease Research Center, Washington University School of Medi-
cine, St Louis, Missouri, between October 1, 1979, and Decem-
ber 31, 2006 (Table1). All the participants were clinically evalu-
ated to be cognitively healthy (Clinical Dementia Rating11
[CDR]=0) at the time of their first psychometric assessment
and had at least 1 additional annual clinical evaluation through
November 29, 2007. The Washington University Human Stud-
ies Committee approved all the procedures. Data from these
participants have been used in other publications.
CLINICAL EVALUATION
Research-trained clinicians and nurses determined whether the
participant was demented (CDR0) or not demented (CDR=0)
based on semistructured interviews with the participant and a
knowledgeable collateral source (usually the spouse or an adult
child), a health history, medication and depression invento-
ries, an aphasia battery, and a neurologic examination of the
participant. The diagnosis of dementia was based on a history
of gradual onset and progressive cognitive decline that inter-
fered with the person’s ability to perform accustomed activi-
ties. The CDR has high interrater reliability,12 is sensitive to
clinical progression, and is highly predictive (93%) of autopsy-
confirmed AD.13 Participants were seen by different physi-
cians from year to year, and physicians did not have access to
previous clinical evaluations or to previous or current psycho-
metric test results.
PSYCHOMETRIC ASSESSMENT
The psychometric battery was administered to all the partici-
pants by trained psychometricians usually 1 to 2 weeks after
the annual clinical assessment. The tests assessed a broad spec-
trum of abilities across multiple cognitive domains, including
Logical Memory, Associate Learning, Mental Control, and Digit
Span from the Wechsler Memory Scale (WMS)14; Informa-
tion, Block Design, and Digit Symbol from the Wechsler Adult
Intelligence Scale15; the Boston Naming Test16; Letter Fluency
for S and P17; Trailmaking Test Part A18; and Form D (copy) of
the Benton Visual Retention Test (Table 2).19 The raw scores
from each test were converted to standard scores using the means
and standard deviations from the initial assessment of the stable
group (Table 2). Initial values for the group that progressed
are included solely for descriptive purposes; recall that they were
initially older, on average, than the stable group.
Based on confirmatory factor analyses of these measures
cross-validated across demented and nondemented samples,5
we formed 4 factor scores for each person at each assessment.
The Global factor included all 12 measures; it was uncorre-
lated with 3 specific factors, which each included 4 measures.
The measures on the Verbal Memory factor were Logical
Memory, Associate Learning, Information, and Boston Nam-
ing. The 4 measures on the Working Memory and Executive
Function factor were Mental Control, Digit Span Forward and
Backward, and Letter Fluency. The Visuospatial factor in-
cluded Block Design, Digit Symbol, Trailmaking A, and Ben-
ton (copy). A prorated factor score was computed if 1 or 2 val-
ues were missing for the Global factor and if 1 value was missing
for the specific factors; otherwise, the factor value for that as-
sessment for that person was excluded from the analyses.
NEUROPATHOLOGIC ASSESSMENT
All the brains were examined according to a standard proto-
col.20 After fixation in neutral-buffered 10% formalin, tissue
blocks were obtained from 30 brain regions. Sections (6 µm)
from paraffin-embedded tissue blocks were stained with he-
matoxylin-eosin, Gallyas and modified Bielschowsky silver
stains, and immunohistochemical methods. Histologic crite-
ria for AD were based on the quantification of diffuse and neu-
ritic amyloid deposition in 5 cortical regions with 10-mm2 mi-
Table 1. Characteristics of the Samples at Entry,











Assessments, No. 1581 957 330
Age at entry, mean (SD), y 74.4 (8.6) 80.4 (8.9) 83.6 (9.2)
Age at diagnosis, mean
(SD), y
NA 84.1 90.2 (7.2)
Age at last assessment,
mean (SD), y
79.6 (8.5) 88.2 (8.2) 92.2 (6.3)
Male sex, % 37 34 36
APOE4 carrier, % 28 27 18
Education, mean, y 14.8 14.1 13.8
SBT score at entry,
mean (SD)
1.4 (2.1) 1.6 (2.1) 1.5 (2.1)
SBT score at diagnosis,
mean (SD)
NA 4.6 (4.8) 5.5 (6.1)
SBT score at last
assessment, mean (SD)
1.2 (1.9) 7.1 (7.0) 9.9 (8.7)
CDR-SB at entry, mean (SD) 0.05 (0.2) 0.17 (0.3) 0
CDR-SB at diagnosis,
mean (SD)
NA 1.5 (1.8) 1.7 (2.4)
CDR-SB at last assessment,
mean (SD)
0.03 (0.1) 3.3 (3.7) 4.5 (5.1)
Abbreviations: APOE4, apolipoprotein E4; CDR-SB, Clinical Dementia
Rating sum of boxes; NA, not applicable; SBT, Short Blessed Test.
Table 2. Initial Neuropsychological Performance
for the Stable and Progressed Groups
Measure
Score, Mean (SD)
Stable Group Progressed Group
Logical Memory 8.87 (2.91) 7.39 (2.93)
Associate Learning 13.42 (3.53) 11.90 (3.30)
Information 20.60 (4.43) 18.94 (5.04)
Boston Naming 54.55 (5.69) 51.00 (7.02)
Mental Control 7.21 (1.78) 7.07 (1.97)
Digit Span Forward 6.55 (1.25) 6.40 (1.15)
Digit Span Backward 4.75 (1.28) 4.62 (1.18)
Letter Fluency 29.41 (9.73) 27.21 (9.79)
Block Design 30.05 (8.63) 26.86 (7.02)
Digit Symbol 45.67 (11.53) 26.86 (7.02)
Trailmaking A, s 40.94 (19.88) 51.21 (21.82)
Benton, copy 9.59 (0.88) 9.78 (0.47)
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croscopic fields in each region and the National Institute on
Aging–Reagan21 neuropathologic probability estimates of AD.
The 2 sets of criteria have near-complete agreement for inter-
mediate and high probability of AD.
STATISTICAL ANALYSES
Cross-sectional comparisons of quantitative demographic vari-
ables (age and education) in the 2 groups (stable vs progressed)
were made using t tests for independent groups; the 2 test was
used for categorical variables. A multistep longitudinal model-
ing procedure was used for each of the 4 factors. All longitudi-
nal analyses were conducted using random coefficient models
(SAS v9.1.3, PROC MIXED; SAS Institute Inc, Cary, North Caro-
lina) and included the covariates of age and education.
To determine the best form of a factor score’s trajectory
through time for each group (stable and progressed), we used
2 tests for −2 log likelihood ratios (−2LLs) for nested models
of increasing complexity of the slope across time (linear, qua-
dratic, linear piecewise, linear piecewise optimized, and qua-
dratic piecewise); simpler models are nested in more complex
models. Model comparisons used 2 tests of deviance scores
beginning with the simple linear model. Deviance scores equal
the difference between the −2LL of a simpler model and a more
complex one (2).
The linear piecewise change model specified a point of in-
flection and tested whether rates of cognitive decline differed
before and after that point.22 To determine the optimum place-
ment of the change point in the piecewise model, we tested in-
flection points from 1 to 6 years before the last assessment for
the stable group. For those who progressed, we tested for an
inflection point at the time of diagnosis of dementia and from
4 years before diagnosis to 2 years after diagnosis (50 obser-
vations at each selected time point). The quadratic piecewise
model added a quadratic term for the postinflection time vari-
able using the optimal inflection point.
We conducted additional analyses to determine whether in-
stead of a quadratic function after inflection there was accelera-
tion in the rate of progression (ie, a change in the slope of the
slopes across time). Technically, this was not a test of a nested
model. First, we used the optimal piecewise model to predict the
factor scores at each time of assessment for each person (best
linear unbiased predictor). Using these latent values from each
time of assessment rather than observed values, we calculated
latent difference scores (LDSs) for each person. The LDS equals
the difference between the predicted values at 2 adjacent times
of assessment (ŶT1−ŶT2, ŶT2−ŶT3, ŶT3−ŶT4, and so forth) begin-
ning with the difference of the predicted value at the optimized
inflection point (ŶT1) and the next assessment thereafter (ŶT2).
Then we tested a linear mixed model using the LDS as the
dependent variable to determine whether the slope of the LDS
values (ie, the slope of the slopes) changed across time. The
acceleration coefficient tested herein is a 2-stage regression ana-
logue to other acceleration models derived from structural equa-
tion modeling23 and the functional equivalent of acceleration
in kinematics (ie, the second derivative of position/intercept).
Although this method of measurement may slightly attenuate
true acceleration values because of the tendency for latent val-
ues to “shrink” in the presence of missing data,24 its computa-
tion is robust, is straightforward, and can be estimated with-
out multiple imputation of missing data. It yields results
consistent with simultaneous models.25 A simultaneous model
that approximates slopes and acceleration was not attempted
because we did not know the functional form of the data (the
primary aim of this investigation).
After determining the optimal models within each group,
slope estimates were based on a mixed model for each factor
that included covariates, effects for group (stable vs pro-
gressed), time (before and after inflection), and group time
interactions. Acceleration coefficients for the group that pro-
gressed were estimated from the second stage of the LDS model
and were added to slope coefficients after the point of inflec-
tion. All analyses were repeated for the subset of the group that
progressed that had autopsy confirmation of AD.
RESULTS
SAMPLE CHARACTERISTICS
All the participants were not demented (CDR=0) at en-
try and either remained CDR=0 (stable) throughout fol-
low-up (n=310, 37% men) or progressed to CDR0
(n=134, 34% men) with a clinical diagnosis of uncer-
tain dementia (CDR=0.5) or dementia of the Alzheimer
type (CDR0.5) by the time of their last evaluation
(Table 1). Participants who progressed and whose clini-
cal diagnosis was non-AD dementia (eg, vascular demen-
tia associated with Parkinson disease) were excluded. In-
dividuals who came to autopsy with a clinical diagnosis
of dementia of the Alzheimer type but who had another
dementia abnormality were also excluded (n=14). Maxi-
mum follow-up was 25.7 years (mean [SD], 5.9 [5.3]
years). The stable group was slightly more educated
(mean, 14.8 years) than the group that progressed (mean,
14.1 years). As might be expected given that AD is age
associated, those who progressed were older at entry
(mean [SD], 80.4 [8.9] years) than those whose perfor-
mance remained stable (mean [SD], 74.4 [8.6] years).
Apolipoprotein E4 status did not differ between the stable
(28% carriers) and progressed (27% carriers) groups. Au-
topsy confirmation of a diagnosis of AD was available for
a subset (n=44, 36% men) of the group that progressed.
At the time of progression, they were older (mean age,
90.2 years) than the rest of the group (mean age, 84.1
years), although their mean educational level (13.8 years)
was comparable with that of those without autopsy (14.1
years).
NONDEMENTED AGING
The linear regression model provided the best fit for each
factor in the stable group. The −2LL values were as fol-
lows: Global, 4255.5; Verbal Memory, 3045.3; Visuo-
spatial, 2796.7; and Working Memory, 5912.5. More com-




In the progressed group, the linear model provided ad-
equate fit for all 4 factors (−2LL values) (Table 3). Fit
was not improved using a quadratic model for any fac-
tor (P .05 for all), although it was improved using a
piecewise model with an inflection point at the time of
diagnosis. The piecewise model fit was improved by mov-
ing the inflection point before diagnosis (P  .001)
(Table 3). The optimal inflection point varied for the 4
factors: 2 years before clinical diagnosis for the Global
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factor, 1 year before diagnosis for the Verbal and Work-
ing Memory factors, and 3 years before diagnosis for the
Visuospatial factor (Figure).
The Verbal Memory factor included episodic and se-
mantic memory measures. An inflection point for a single
measure of episodic memory occurred substantially longer
than 1 year before diagnosis in previous studies.1,2 There-
fore, we also examined each of the 2 measures of epi-
sodic memory independently. The inflection point oc-
curred 4 years before diagnosis for WMS Associate
Learning and 2 years before diagnosis for WMS Logical
Memory.
The fit of the piecewise model did not improve with
the addition of a quadratic term after the optimal inflec-
tion point (P> .05 for all) (Table 3). There was, how-
ever, a significant increase in the rate of decline after the
inflection point for all 4 factors using the LDS models of
acceleration (t12.10 for all, P .001). Thus, the opti-
mal model in the group that progressed was piecewise,
with linear slope before inflection and accelerated slope
Table 3. −2LL Values for Each Cognitive Factor for Each Model and Significant Maximum Likelihood Deviance Tests (2)a
for the Group That Progressed
Model df
Global Factor Verbal Memory Factor Visuospatial Factor Working Memory Factor
−2LL 2 −2LL 2 −2LL 2 −2LL 2
Simple linear 8 2750.8 NA 2277.7 NA 1938.8 NA 3737.8 NA
Quadratic 9 3019.5 268.7 2277.7 0 1938.8 0 3737.8 0
Piecewise linear
At diagnosis 9 2705.1 −45.7 2255.9 −21.8 1939.6 −44.2 3690.1 −47.7
Optimizedb 9 2690.3 −14.8 2243.5 −12.4 1910.3 −29.3 3676.0 −20.1
Piecewise quadraticc 10 2689.5 −0.8 2243.9 0.4 1910.3 0 3675.6 −0.4
Abbreviations: −2LL, −2 log likelihood ratio (smaller values indicate better fit); NA, not applicable.
a1 df for deviance tests.
bThe optimal inflection point was 2 years before diagnosis for the Global factor, 3 years before diagnosis for the Visuospatial factor, and 1 year before diagnosis
for the Verbal and Working Memory factors.
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Figure. Longitudinal course of the stable, progressed, and autopsy-confirmed Alzheimer disease (AD) groups before and after diagnosis of AD (DX) on Global
factor (A), the Verbal Memory factor (B), the Visuospatial factor (C), and the Working Memory factor (D). All available data were used for the analysis, but the
plotted values for the stable and progressed groups include at least 50 observations per time point per group.
(REPRINTED) ARCH NEUROL / VOL 66 (NO. 10), OCT 2009 WWW.ARCHNEUROL.COM
1257
©2009 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/ by a University of Kansas HQ User  on 06/28/2017
afterward. The same was true when the data were lim-
ited to those who progressed and had autopsy confirma-
tion of AD, including the placement of the optimal in-
flection point for each factor.
CHARACTERIZING PRECLINICAL AD:
SLOPE AND ACCELERATION ESTIMATES
Estimates and their standard errors are given in Table 4.
Change in performance in all 4 factors is demonstrated
in the Figure. The stable and progressed groups shared
similar preinflection trajectories; the group time (be-
fore inflection) interactions were not significant for any
of the 4 factors (P .19 for all). There was a significant
downward linear trend in global cognitive abilities and
in verbal and working memory (P .01); however, no
longitudinal decline was detected in the Visuospatial fac-
tor (P=.29) (Figure). Results were similar when data from
the group that progressed were limited to individuals with
autopsy-confirmed AD.
A different pattern of longitudinal cognitive perfor-
mance was seen in the group that progressed to demen-
tia. Compared with preinflection slopes, they had steeper
downward slopes after inflection (P .001), and the rate
of decline accelerated with time (Table 4 and Figure).
The greatest preclinical slope change was in the Work-
ing Memory factor (slope=−0.66, acceleration=−0.17) be-
ginning 1 year before dementia diagnosis followed by the
Global factor (slope=−0.32, acceleration=−0.06). Postin-
flection slopes and accelerations were similar for the Ver-
bal Memory and Visuospatial factors. Slopes were steeper
when the sample that progressed was restricted to those
with autopsy-confirmed AD, but rates of acceleration
were comparable with those for the total group that
progressed.
COMMENT
We demonstrate models of preclinical decline in a well-
characterized longitudinal sample with inflection points
in cognitive performance occurring several years before
clinical diagnosis of dementia. It is apparent from these
models that there is a clear turning point in the transi-
tion from normal aging to preclinical AD. A novel find-
ing was that visuospatial abilities demonstrated an in-
flection point 3 years before clinical diagnosis. This decline
on tests that were primarily speeded represented a sharp
departure from the previous longitudinal pattern of these
initially nondemented individuals, which was similar to
that of those who did not become demented. Global cog-
nitive abilities followed decline in visuospatial ability dur-
ing the next year. Inflection points in the Verbal and
Working Memory factors were not seen until 1 year be-
fore clinical diagnosis. The delayed inflection point for
Verbal Memory probably results from the combination
of episodic and semantic memory measures on one fac-
tor. If sufficient measures of each type of memory were
available to form separate factors, an earlier inflection point
for episodic memory would probably emerge based on
the results obtained for the 2 individual measures of epi-
sodic memory.
The rate of decline accelerated after the downward
course began. This was true for all 4 factors but was most
apparent for Working Memory. Of course, the esti-
mated rates of decline and acceleration depend on the
tests administered, their level of difficulty, and floor and
ceiling effects. For example, 3 tests in the battery (the
Boston Naming Test, the copy version of the Benton Vi-
sual Retention Test, and the WMS Mental Control) have
ceiling effects in the preinflection period in nonde-
mented older adults. We were limited to these archival
data from a battery that was originally constructed in 1979
for a study of mild dementia, and it does not contain more
modern measurements of working memory.
The number of years before diagnosis of dementia that
the inflection point occurs in the longitudinal course de-
pends on the method of diagnosis and on the character-
istics of the cognitive tests. The period will be longer if
one relies on test norms, particularly if the sample is at a
high level of function initially, than if one relies on col-
lateral source reports of change from previous levels of
function, captured by the CDR. Furthermore, inclusion
of people in the preclinical stage in nondemented samples
overestimates decline in cognitive ability traditionally at-
tributed solely to age.26 This makes it more difficult to
detect beginning dementia using conventional norms
based on these contaminated samples.
A great strength of this study is the replication of the
pattern of the longitudinal results observed in the larger
sample that progressed in the subset with autopsy-
confirmed AD. Although the rates of decline were some-
what steeper in the autopsied subset, the rates of accel-
eration were the same. The rate of progression in AD is
Table 4. Estimated Slopes and Rates of Acceleration








Stable −0.05 (0.01) NA NA
Progressed −0.07 (0.02) −0.32 (0.02) −0.06 (0.003)
AD confirmed −0.10 (0.03) −0.40 (0.04) −0.07 (0.004)
Verbal Memory factor
Stable −0.02 (0.01) NA NA
Progressed −0.02 (0.01) −0.15 (0.02) −0.04 (0.001)
AD confirmed −0.03 (0.02) −0.19 (0.03) −0.04 (0.002)
Visuospatial factor
Stable 0.00 (0.01) NA NA
Progressed −0.02 (0.01) −0.13 (0.01) −0.03 (0.001)
AD confirmed −0.02 (0.02) −0.17 (0.02) −0.04 (0.002)
Working Memory factor
Stable −0.08 (0.02) NA NA
Progressed −0.10 (0.03) −0.66 (0.04) −0.17 (0.01)
AD confirmed −0.12 (0.04) −0.89 (0.06) −0.17 (0.01)
Abbreviations: AD, Alzheimer disease; NA, not applicable.
aData are given as estimate (SE). Slope coefficients were estimated using the
piecewise change model of raw data. Acceleration coefficients were estimated
using latent difference score regression, in which intercepts were equivalent to
piecewise change slope estimates (±0.02 U).
bThe optimal inflection point was 2 years before diagnosis for the Global
factor, 1 year before diagnosis for the Verbal and Working Memory factors, and
3 years before diagnosis for the Visuospatial factor.
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highly variable27; perhaps those with autopsy-con-
firmed AD were individuals who progressed more rap-
idly. Another possibility is that the progressed group may
contain individuals who do not have AD and, therefore,
do not follow the same pattern of decline.
There are several implications of this study. Some of
the earliest signs of preclinical disease may occur on tests
of visuospatial and speeded psychomotor skills. Further-
more, the greatest rate of preclinical decline may occur
on executive and attention tasks. These findings sug-
gest that research into early detection of cognitive dis-
orders using only episodic memory tasks, such as word
lists or paragraph recall, may not be sensitive to either
all of the earliest manifestations of disease or the most
rapidly changing domain. Furthermore, the preclinical
downward course comes after an inflection point. Be-
fore that point, the longitudinal course of those who did
and did not develop AD was the same. In summary, con-
verging longitudinal evidence suggests that after a sharp
departure from the relatively flat course of normal aging
there is a preclinical period in AD with insufficient cog-
nitive decline to warrant clinical diagnosis using conven-
tional criteria but that can be seen with longitudinal data
from multiple domains of cognition and not just memory.
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